Review



intragastric administration  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress intragastric administration
    Intragastric Administration, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pm36053011-38-45-55
    Average 94 stars, based on 5 article reviews
    intragastric administration - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Sesquiterpene compound α-cyperone relieves the injury in neurons undergoing oxygen-glucose deprivation/reoxygenation
    Article Snippet: .. Subsequently, α-cyperone (0-30 μM; MedChemExpress, China) (Huang et al., 2018) or 3-TYP (sirtuin-3 (SIRT3) inhibitor; 50 μM; MedChemExpress) (Zeng et al., 2019) was added to the cells followed by a normal incubation with 5% CO2 at 37oC for a further 24 hours (Wang et al., 2021). ..

    Control:

    Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation
    Article Snippet: .. Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out. .. Cyclophosphamide (CTX; C3250000) was purchased from Sigma (United States) and dissolved in DMEM as per manufacturer’s instructions. α-Cyperone was purchased from MedChemExpress (HY-N0710, Monmouth Junction, NJ, United States) and dissolved in Methyl sulfoxide (DMSO; Cat# D8371, Solarbio Life Sciences, Beijing, China), and in the final cultivation system, the content of DMSO should not exceed 0.01%.

    Recombinant:

    Article Title: α-Cyperone (CYP) down-regulates NF-κB and MAPKs signaling, attenuating inflammation and extracellular matrix degradation in chondrocytes, to ameliorate osteoarthritis in mice
    Article Snippet: .. Alpha-Cyperone (CYP) (purity >98%) and recombinant rat IL-1 β were obtained from MedChemExpress (Monmouth Junction, NJ, USA) and PeproTech (Rocky Hill, NJ, USA), respectively. .. Primary antibodies against aggrecan, ADAMTS5, collagen II, MMP-3, β -actin, Lamin B1 and GADPH were obtained from Abcam (Cambridge, UK), whereas those antibodies against iNOS, COX-2, TNF, IL-6, MMP-13 were purchased from Proteintech Group (Wuhan, China).

    Saline:

    Article Title: α-Cyperone ameliorates depression in mammary gland hyperplasia and chronic unpredictable mild stress rat by regulating hormone, inflammation, and oxidative stress.
    Article Snippet: Background: Hyperplasia of mammary gland (HMG) is caused by endocrine disorders, and patients are prone to anxiety and depression. a-Cyperone has a variety of pharmacological activities including antidepressant.. The purpose of this study was to explore the effect and its possible mechanism of a-Cyperone on HMG-associated depression rats.. Methods: The depression model was constructed using chronic unpredictable mild stress (CUMS), while the HMG model was induced by estrogen, with or without a-Cyperone intervention.



    Similar Products

    concentrations α cyperone  (MedChemExpress)
    94
    MedChemExpress concentrations α cyperone
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    Concentrations α Cyperone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pmc12852401-129-55-57
    Average 94 stars, based on 1 article reviews
    concentrations α cyperone - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    hy n0710  (MedChemExpress)
    94
    MedChemExpress hy n0710
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    Hy N0710, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pmc12852401-130-22-21
    Average 94 stars, based on 1 article reviews
    hy n0710 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    a cyperone l  (MedChemExpress)
    94
    MedChemExpress a cyperone l
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    A Cyperone L, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pm36053011-38-36-55
    Average 94 stars, based on 1 article reviews
    a cyperone l - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    intragastric administration  (MedChemExpress)
    94
    MedChemExpress intragastric administration
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    Intragastric Administration, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pm36053011-38-45-55
    Average 94 stars, based on 1 article reviews
    intragastric administration - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    a cyperone  (MedChemExpress)
    94
    MedChemExpress a cyperone
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    A Cyperone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pm36053011-38-53-55
    Average 94 stars, based on 1 article reviews
    a cyperone - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    α cyperone  (MedChemExpress)
    94
    MedChemExpress α cyperone
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    α Cyperone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/10__3329_slash_bjp__v17i2__58188-35-1-4
    Average 94 stars, based on 1 article reviews
    α cyperone - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    alpha cyperone cyp  (MedChemExpress)
    94
    MedChemExpress alpha cyperone cyp
    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets <t>of</t> <t>α-Cyperone</t> in the treatment of DOR.
    Alpha Cyperone Cyp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0710/alpha-Cyperone/pmc08312409-120-0-12
    Average 94 stars, based on 1 article reviews
    alpha cyperone cyp - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets of α-Cyperone in the treatment of DOR.

    Journal: Frontiers in Pharmacology

    Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation

    doi: 10.3389/fphar.2025.1658536

    Figure Lengend Snippet: Flowchart of a network pharmacology-based approach to investigate the pharmacologic targets of α-Cyperone in the treatment of DOR.

    Article Snippet: Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out.

    Techniques:

    Screening and analysis of potential targets of α-Cyperone on DOR. (A) 2D and 3D structure of α-Cyperone. (B) Venn diagram of the interaction between α-Cyperone-target and DOR-target. (C) PPI Network diagram of target genes. “α-Cyperone target - DOR targe.

    Journal: Frontiers in Pharmacology

    Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation

    doi: 10.3389/fphar.2025.1658536

    Figure Lengend Snippet: Screening and analysis of potential targets of α-Cyperone on DOR. (A) 2D and 3D structure of α-Cyperone. (B) Venn diagram of the interaction between α-Cyperone-target and DOR-target. (C) PPI Network diagram of target genes. “α-Cyperone target - DOR targe.

    Article Snippet: Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out.

    Techniques:

    Network Pharmacology Predicts the Potential Mechanisms of α-Cyperone in Treating DOR. (A) GO enrichment analysis, including Biological Processes (BP), Cellular Components (CC), and Molecular Functions (MF). (B) KEGG enrichment analysis. Bubble size represents the number of enriched genes, and bubble color indicates the P-value. (C) Network maps of all crossed target genes in the top three pathways of the GO enrichment analysis were screened, and the top 20 key genes obtained by MCC algorithm.

    Journal: Frontiers in Pharmacology

    Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation

    doi: 10.3389/fphar.2025.1658536

    Figure Lengend Snippet: Network Pharmacology Predicts the Potential Mechanisms of α-Cyperone in Treating DOR. (A) GO enrichment analysis, including Biological Processes (BP), Cellular Components (CC), and Molecular Functions (MF). (B) KEGG enrichment analysis. Bubble size represents the number of enriched genes, and bubble color indicates the P-value. (C) Network maps of all crossed target genes in the top three pathways of the GO enrichment analysis were screened, and the top 20 key genes obtained by MCC algorithm.

    Article Snippet: Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out.

    Techniques:

    Molecular docking validation of the binding capacity between AC and targets, and shown the 3-dimensional map of the binding sites. AC is shown in violet. Target proteins are displayed as green. The places where AC and the target proteins are connected represent specific docking sites between AC and target proteins and are shown in magenta. AC:α-Cyperone.

    Journal: Frontiers in Pharmacology

    Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation

    doi: 10.3389/fphar.2025.1658536

    Figure Lengend Snippet: Molecular docking validation of the binding capacity between AC and targets, and shown the 3-dimensional map of the binding sites. AC is shown in violet. Target proteins are displayed as green. The places where AC and the target proteins are connected represent specific docking sites between AC and target proteins and are shown in magenta. AC:α-Cyperone.

    Article Snippet: Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out.

    Techniques: Biomarker Discovery, Binding Assay

    Effect of AC on target proteins. The mRNA expression levels of MAP2K1 (A) , GSK3B (B) , MAPK14 (C) , SRC (D) , AKT1 (E) , ESR2 (F) , ERBB2 (G) , CDH1 (H) , CYP19A1 (I) , ESR1 (J) , MAPK8 (K) , PARP1 (L) . AC treatment is able to reverse the abnormal gene expression of GSK3B, MAPK14, AKT1, ESR2, ERBB2, CYP19A1 and MAPK8 in the CTX group. NC: normal control, CTX: cyclophosphamide, AC: α-Cyperone, ns: P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Journal: Frontiers in Pharmacology

    Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation

    doi: 10.3389/fphar.2025.1658536

    Figure Lengend Snippet: Effect of AC on target proteins. The mRNA expression levels of MAP2K1 (A) , GSK3B (B) , MAPK14 (C) , SRC (D) , AKT1 (E) , ESR2 (F) , ERBB2 (G) , CDH1 (H) , CYP19A1 (I) , ESR1 (J) , MAPK8 (K) , PARP1 (L) . AC treatment is able to reverse the abnormal gene expression of GSK3B, MAPK14, AKT1, ESR2, ERBB2, CYP19A1 and MAPK8 in the CTX group. NC: normal control, CTX: cyclophosphamide, AC: α-Cyperone, ns: P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Article Snippet: Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out.

    Techniques: Expressing, Gene Expression, Control